Compare MGRX & ADVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MGRX | ADVB |
|---|---|---|
| Founded | 2021 | 2014 |
| Country | United States | United States |
| Employees | N/A | 31 |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1M | 7.4M |
| IPO Year | 2023 | N/A |
| Metric | MGRX | ADVB |
|---|---|---|
| Price | $0.47 | $4.99 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 591.7K | 16.9K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.17 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $456,021.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $1.26 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.26 | $0.19 |
| 52 Week High | $2.75 | $7.70 |
| Indicator | MGRX | ADVB |
|---|---|---|
| Relative Strength Index (RSI) | 65.16 | 55.38 |
| Support Level | $0.34 | $3.71 |
| Resistance Level | $0.49 | $5.59 |
| Average True Range (ATR) | 0.04 | 0.47 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 100.00 | 78.57 |
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.